- In February 2025, Grifols announced positive results from a Phase 2/3 clinical trial of its subcutaneous immunoglobulin (SCIg) therapy for GBS. The study demonstrated improved physical performance in patients, as measured by the two-minute walk distance (2MWD), after one year of treatment. This advancement offers a more convenient and potentially effective alternative to traditional intravenous immunoglobulin (IVIG) therapy
- In December 2024, CSL Behring initiated a strategic partnership with leading academic hospitals in Europe to advance research on GBS biomarkers and personalized immunotherapy approaches. The initiative focuses on early identification of severe cases and tailoring treatment based on patient-specific immune response profiles
- In November 2024, the U.S. National Institute of Neurological Disorders and Stroke (NINDS) funded a multi-center study to develop AI-powered diagnostic models for Guillain-Barré Syndrome. This project aims to leverage machine learning to analyze clinical and electrophysiological data, improving early detection and prognosis prediction
- In October 2024, Octapharma AG received FDA Fast Track designation for its novel immunoglobulin therapy, OctaGBS, developed specifically for GBS. The therapy is designed to enhance immune modulation with a faster onset of action, and Phase II trials are currently underway, with promising interim safety and efficacy data.
